What happens if I choose no treatment for MDS

Understanding "Watch and Wait" for MDS

This is an important question, and the answer depends significantly on your specific type of MDS. Let me explain what the medical evidence shows.

The "Watch and Wait" Approach is Actually Standard for Many MDS Patients

According to the NCCN Guidelines for Myelodysplastic Syndromes, many patients with lower-risk MDS are managed with supportive care and monitoring rather than immediate treatment. This isn't neglect—it's evidence-based medicine.

Why Doctors Sometimes Recommend Observation:

Clinical Reasoning:

• Lower-risk MDS often progresses slowly or remains stable for years
• Some patients never need treatment during their lifetime
• The side effects of treatment may outweigh benefits if disease is progressing slowly
• Your quality of life matters in the decision-making process

What Happens Without Treatment Depends on Your Risk Category

For Lower-Risk MDS (IPSS-R Very-Low, Low, or Intermediate):

• Many patients remain stable with just monitoring
• You'd receive supportive care (blood transfusions, growth factors) as needed for symptoms
• Regular blood tests track your blood counts
• Bone marrow biopsies monitor disease changes
• Some patients live many years without needing active treatment

For Higher-Risk MDS:

• Without treatment, there's a higher risk of disease progression
• Blast percentage (immature blood cells) may increase
• Risk of transformation to acute myeloid leukemia (AML) is greater
• Symptoms from low blood counts may worsen

Important Monitoring Requirements

If you choose observation, according to NCCN Guidelines, your care team should:

• Check your blood counts regularly (typically every 3-6 months, adjusted based on your risk)
• Perform bone marrow biopsies periodically to assess changes
• Monitor for signs of disease progression
• Watch for development of symptoms

The Critical Distinction: "No Treatment" vs. "Supportive Care"

Important: Choosing not to take disease-modifying drugs (like hypomethylating agents) is different from receiving no care. Supportive care includes:

• Red blood cell transfusions for anemia
• Platelet transfusions for bleeding risk
• Growth factors to boost blood cell production
• Management of infections
• Symptom relief

Questions to Ask Your Oncologist

Since your specific situation requires your doctor's evaluation, here are key questions:

1. "Based on my IPSS-R risk score and genetic mutations, what is my expected disease course without treatment?"
2. "How often would I need monitoring, and what would trigger starting treatment?"
3. "What symptoms should I watch for that would indicate I need to start treatment?"
4. "Are there any genetic features in my MDS that suggest I should start treatment now rather than wait?"
5. "What is my risk of transformation to AML, and how does that change with or without treatment?"

The Bottom Line

According to NCCN Guidelines, observation with supportive care is a legitimate, evidence-based approach for many MDS patients—particularly those with lower-risk disease. However, your individual prognosis depends on factors like:

• Your IPSS-R risk score
• Specific genetic mutations present
• Cytogenetic abnormalities (chromosome changes)
• Your age and overall health
• Severity of your cytopenias (low blood counts)

Your oncologist will determine the most appropriate approach for YOUR case based on these individual factors and your personal preferences about treatment intensity.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.